Ralinepag
Phase 3Small molecule
United TherapeuticsRalinepag is one of 67 small molecule programs targeting Pulmonary Hypertension. It is currently in Phase 3.
2
Indications
5
Total Trials
1
Active Trials
66
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
179 competitors in Pulmonary Arterial Hypertension
#DrugCompanyPhaseTrials
1Gleevec
NovartisPhase 3
Reata
BiogenPhase 3
Levitra
BayerPhase 3
Aurlumyn
BBTG International Inc.
Phase 3
Flolan
Johnson & JohnsonPhase 3
Zesly
MMezzion Pharma Co. Ltd
Phase 3
Inhaled Iloprost
BayerPhase 3
Atrovent
Boehringer IngelheimPhase 3
Rituxan
RochePhase 2
Actos
TakedaPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Efficacy and Safety2 trials
Pulmonary Arterial Hypertension1 trial
Pulmonary Hypertension1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ralinepag. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company